Equities

Singular Health Group Ltd

SHG:ASX

Singular Health Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.091
  • Today's Change0.007 / 8.33%
  • Shares traded716.00k
  • 1 Year change+121.95%
  • Beta0.8053
Data delayed at least 20 minutes, as of Nov 15 2024 04:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Singular Health Group Limited is an Australia-based medical technology company. The Company is focused on helping practitioners and patients via personalized surgical planning solutions that drive health outcomes. Its Volumetric Rendering Platform (VRP) leverages existing two-dimensional (2D) radiological images to generate fully immersive patient-specific three-dimensional (3D) models. Its software products include 3DicomViewer, 3DicomVSP, GeoVR and Health Academy. 3Dicom Viewer is a cross-platform application which allows end-users to interact with standard 2D medical images, such as magnetic resonance imaging (MRI) and computerized tomography (CT) scans in 3D. Health Academy has been developed to focus primarily on the year 11 and year 12 Australian Tertiary Admissions Rank (ATAR) human biology courses. 3DicomVSP is a software that underpins the Scan to Surgery approach with the intuitive user-interface providing modules for each of the phases of 3D/ Virtual Reality scan review.

  • Revenue in AUD (TTM)945.75k
  • Net income in AUD-2.88m
  • Incorporated2020
  • Employees--
  • Location
    Singular Health Group LtdUnit 3/26 Railway RoadSUBIACO 6008AustraliaAUS
  • Phone+61 30016-7975
  • Websitehttps://singular.health/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Uscom Ltd3.77m-2.07m11.27m11.00--3.60--2.99-0.0118-0.01180.02140.01250.73160.887411.28---40.23-30.60-53.05-36.9783.8086.20-54.99-53.502.54-17.760.2443--38.730.997719.92---12.44--
Atomo Diagnostics Ltd4.24m-6.85m13.42m----1.33--3.17-0.0108-0.01080.00670.01580.30441.253.09---49.17-31.42-54.41-34.2041.4842.58-161.56-120.994.84--0.0083--66.6351.0131.23---54.38--
Control Bionics Ltd5.97m-5.91m16.34m----2.10--2.74-0.0381-0.03810.03740.03150.67322.412.98---66.73-41.07-85.40-45.9775.6268.78-99.13-92.331.40-112.620.133--2.0846.24-5.02--67.72--
Resonance Health Ltd8.80m169.31k17.47m18.00111.761.5526.171.980.00030.00030.01880.02450.5631--5.08--1.08-3.191.40-3.56----1.92-7.63----0.2527--95.1519.18121.70-33.171.63--
Singular Health Group Ltd945.75k-2.88m18.82m----12.35--19.89-0.018-0.03080.00630.00740.35368.7322.14---107.62---331.71--124.56---304.36--2.42--0.1316--112.26--42.12------
ImExHS Ltd24.68m-3.42m19.05m400.00--1.26--0.7718-0.0794-0.07940.57130.33141.1097.113.7861,692.52-15.28-22.17-20.83-29.2131.9529.75-13.85-31.201.53-4.580.0593--14.7926.48-37.97--5.61--
Lumos Diagnostics Holdings Ltd17.25m-13.32m23.86m----1.49--1.38-0.0276-0.02760.0350.02150.4264.377.02---32.88-40.29-54.62-58.0763.7749.44-77.19-151.150.6949-6.010.5314--5.6619.534.22---47.99--
Data as of Nov 15 2024. Currency figures normalised to Singular Health Group Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.